Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway

Oncology Reports

Volumn 28, Issue 3, 2012, Pages 999-1005

  Liang, Liang ^a,b   Li, Lei ^a,b   Zeng, Jin ^a,b   Gao, Yang ^a,b   Chen, Yu Le ^a,b   Wang, Zhi Qiang ^a,b   Wang, Xin Yang ^a,b   Chang, Luke S ^a,b   He, Dalin ^a,b  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

EGFR; Invasion; Migration; MMP 9; Renal cell carcinoma; Silibinin

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SILIBININ; STAT3 PROTEIN;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CARCINOMA CELL; CELL MIGRATION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; HUMANS; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SILYMARIN;

EID: 84865316518     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1874     Document Type: Article

References (28)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 49: 8-31, 1999.
2. Maldazys JD and DeKernion JB: Prognostic factors in metastatic renal carcinoma. J Urol 136: 376-379, 1986.
3. Li L, Gao Y, Zhang L, Zeng J, He D and Sun Y: Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma. Cancer Lett 272: 61-69, 2008.
4. Dancey JE: Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: do we need a better mouse trap? J Clin Oncol 22: 2975-2977, 2004.
5. Ishikawa J, Maeda S, Umezu K, Sugiyama T and Kamidono S: Amplification and overexpression of the epidermal growth factor receptor gene in human renal-cell carcinoma. Int J Cancer 45: 1018-1021, 1990.
6. Minner S, Rump D, Tennstedt P, et al: Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer 118: 1268-1275, 2012.
7. Hutson TE: Targeted therapies. Oncologist 16 (Suppl 2): 14-22, 2011.
8. Itsumi M and Tatsugami K: Immunotherapy. Clin Dev Immunol 2010: 284581, 2010.
9. Yang JC, Sherry RM, Steinberg SM, et al: Low reponse rate randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21: 3127-3132, 2003.
10. Velmurugan B, Gangar SC, Kaur M, Tyagi A, Deep G and Agarwal R: Silibinin exerts sustained growth suppressive effect against human colon carcinoma SW480 xenograft by targeting multiple signaling molecules. Pharm Res 27: 2085-2097, 2010.
11. Wu KJ, Zeng J, Zhu GD, et al: Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta Pharmacol Sin 30: 1162-1168, 2009.
12. Chen PN, Hsieh YS, Chiang CL, Chiou HL, Yang SF and Chu SC: Silibinin inhibits invasion of oral cancer cells by suppressing the MAPK pathway. J Dent Res 85: 220-225, 2006.
13. Singh RP, Raina K, Sharma G and Agarwal R: Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res 14: 7773-7780, 2008.
14. Stamenkovic I: Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10: 415-433, 2000.
15. Asakuma J, Sumitomo M, Asano T, Asano T and Hayakawa M: Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma. J Urol 171: 897-902, 2004.
16. Prewett M, Rothman M, Waksal H, Feldman M, Bander NH and Hicklin DJ: Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 4: 2957-2966, 1998.
17. Rowinsky EK, Schwartz GH, Gollob JA, et al: Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22: 3003-3015, 2004.
18. Motzer RJ, Amato R, Todd M, et al: Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21: 99-101, 2003.
19. Singh RP and Agarwal R: A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer. Mutat Res 555: 21-32, 2004.
20. Tyagi A, Sharma Y, Agarwal C and Agarwal R: Silibinin impairs constitutively active TGFalpha-EGFR autocrine loop in advanced human prostate carcinoma cells. Pharm Res 25: 2143-2150, 2008.
21. Singh RP, Gu M and Agarwal R: Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res 68: 2043-2050, 2008.
22. Hsieh YS, Chu SC, Yang SF, Chen PN, Liu YC and Lu KH: Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2. Carcinogenesis 28: 977-987, 2007.
23. Chang HR, Chen PN, Yang SF, et al: Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel. Mol Carcinog 50: 811-823, 2011.
24. Qi L, Singh RP, Lu Y, et al: Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line. Cancer Biol Ther 2: 526-531, 2003.
25. Qiu Q, Yang M, Tsang BK and Gruslin A: EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves activation of both PI3K and MAPK signalling pathways. Reproduction 128: 355-363, 2004.
26. Tian YC, Chen YC, Chang CT, et al: Epidermal growth factor and transforming growth factor-beta1 enhance HK-2 cell migration through a synergistic increase of matrix metalloproteinase and sustained activation of ERK signaling pathway. Exp Cell Res 313: 2367-2377, 2007.
27. Kang CS, Pu PY, Li YH, et al: An in vitro study on the suppressive effect of glioma cell growth induced by plasmid-based small interference RNA (siRNA) targeting human epidermal growth factor receptor. J Neurooncol 74: 267-273, 2005.
28. Sumitomo M, Asano T, Asakuma J, Asano T, Horiguchi A and Hayakawa M: ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. Clin Cancer Res 10: 794-801, 2004.